Thosemine
:
bladder cancer FDA approval. $100M more non dilutive funding. Now has a cash runway of $250M. Phase 3 positive results on Lung cancer and seeking further FDA approval. 12 month supply of the drug and most importantly ready to hit the market in two weeks. Also have earnings report coming in mid May that will have very positive guidance for Q2 and Q3. Very possible buyout candidate from an Eli Lilly or Johnson & Johnson, Merck, etc. This also has had an all time high of $45 that is where this is headed again. This also has short interest of 38%, so very likely to squeeze. The shorts have at maximum 16 days to cover which is just before earnings report. This has potential to squeeze like GameStop. This is the stock to watch next week and for next month really. I'm not a financial advisor but, this is as close to a sure thing as you can get right now with all the positives coming out. If they get lung cancer approval, this will be $100+
JESSE JAMES8832 : shorts covering
Thosemine : bladder cancer FDA approval. $100M more non dilutive funding. Now has a cash runway of $250M. Phase 3 positive results on Lung cancer and seeking further FDA approval. 12 month supply of the drug and most importantly ready to hit the market in two weeks. Also have earnings report coming in mid May that will have very positive guidance for Q2 and Q3. Very possible buyout candidate from an Eli Lilly or Johnson & Johnson, Merck, etc. This also has had an all time high of $45 that is where this is headed again. This also has short interest of 38%, so very likely to squeeze. The shorts have at maximum 16 days to cover which is just before earnings report. This has potential to squeeze like GameStop. This is the stock to watch next week and for next month really. I'm not a financial advisor but, this is as close to a sure thing as you can get right now with all the positives coming out. If they get lung cancer approval, this will be $100+